Payment overview · 2025
General Payments
$1,397.33
48 reported records · 18 companies
Healthcare provider profile · identity verified
Stephen Rohrer, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · WYNNE, AR · NPI 1538611975
Verified facts
What the public records show
CMS Open Payments records show Stephen Rohrer, CNP received $1,397.33 in general payments during 2025 across 48 reported records.
Medtronic, Inc. accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$213.93 | 15.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $167.73 | 12.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $149.74 | 10.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $149.57 | 10.7% | 11 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $147.30 | 10.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $131.40 | 9.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.95 | 5.7% | 4 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $69.81 | 5.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.67 | 4.4% | 4 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $50.31 | 3.6% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.54 | 2.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.89 | 2.1% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $24.81 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.09 | 1.5% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $20.96 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.79 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.25 | 1.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.59 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,397.33 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SIMPLERA SENSOR Normalized: simplera sensor |
Device | Medtronic, Inc. | $195.73 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $149.74 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $149.57 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $131.40 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SIMPLIMAX Normalized: simplimax |
Medical Supply | Organogenesis Inc. | $123.47 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $69.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $42.73 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.54 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.27 | 2 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $28.10 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| Miro 3D Normalized: miro 3d |
Device | Reprise Biomedical, Inc. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| NUSHIELD Normalized: nushield |
Medical Supply | Organogenesis Inc. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $8.97 | 1 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $8.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 52 |
| Gabapentin | Gabapentin | 164 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 129 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 33 |
| Furosemide | Furosemide | 117 | 35 |
| Omeprazole | Omeprazole | 112 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 41 |
| Lorazepam | Lorazepam | 93 | 19 |
| Mounjaro | Tirzepatide | 92 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 25 |
| Losartan Potassium | Losartan Potassium | 83 | 25 |
| Meloxicam | Meloxicam | 81 | 29 |
| Jardiance | Empagliflozin | 78 | 18 |
| Gentamicin Sulfate | Gentamicin Sulfate | 74 | 29 |
| Lisinopril | Lisinopril | 74 | 23 |
| Tramadol Hcl | Tramadol Hcl | 73 | 26 |
| Carvedilol | Carvedilol | 68 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 20 |
| Potassium Chloride | Potassium Chloride | 66 | 24 |
| Metformin Hcl | Metformin Hcl | 63 | 19 |
| Celecoxib | Celecoxib | 61 | 26 |
| Montelukast Sodium | Montelukast Sodium | 57 | 16 |
| Pregabalin | Pregabalin | 57 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 14 |
| Trazodone Hcl | Trazodone Hcl | 54 | 23 |
| Mupirocin | Mupirocin | 53 | 44 |
| Ozempic | Semaglutide | 53 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 12 |
| Levofloxacin | Levofloxacin | 41 | 31 |
| Ondansetron Odt | Ondansetron | 41 | 18 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 12 |
| Santyl | Collagenase Clostridium Hist. | 40 | 16 |
| Sertraline Hcl | Sertraline Hcl | 40 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 19 |
| Allopurinol | Allopurinol | 38 | 14 |
| Clonazepam | Clonazepam | 38 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 11 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 13 |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 32 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | 11 |
| Methylprednisolone | Methylprednisolone | 30 | 25 |
| Prednisone | Prednisone | 30 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 16 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Daptomycin | Daptomycin | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Linezolid | Linezolid | 21 | 14 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 13 |
| Azithromycin | Azithromycin | 16 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,397.33 · 48 records | Medtronic, Inc. | ABRYSVO, AFREZZA, AIRSUPRA, BREZTRI, Barostim Neo System, CAPLYTA, CARDIOMEMS, COMIRNATY, Cologuard Collection Kit, FARXIGA, GVOKE HYPOPEN, MINIMED 780G, Miro 3D, Miro3D, NUSHIELD, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SIMPLERA SENSOR, SIMPLIMAX, STRAVIX PL, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIA MATRIX, VOQUEZNA, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error